Patents by Inventor Lukas Flatz
Lukas Flatz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240102262Abstract: The disclosure relates to an work implement, in particular a cable excavator, comprising a mechanical diaphragm wall gripper with two gripper buckets, which is suspended on the work implement by means of a hoisting cable and a closing cable, a hoisting cable winch on which the hoisting cable can be wound up and unwound for adjusting the diaphragm wall gripper, in particular substantially vertically, a closing cable winch on which the closing cable for actuating the gripper buckets is mounted so that it can be wound up and unwound, a measuring device with at least one sensor for detecting a current position, speed and/or acceleration, a control unit connected to the measuring device, via which the hoisting and closing cable winches can be actuated, and an input means connected to the control unit for controlling the diaphragm wall gripper.Type: ApplicationFiled: September 12, 2023Publication date: March 28, 2024Inventors: Lukas FLATZ, Mathias BLANK, Tobias GLÜCK, Bernhard BISCHOF, Andreas KUGI
-
Publication number: 20220315951Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.Type: ApplicationFiled: June 22, 2022Publication date: October 6, 2022Applicant: UNIVERSITÄT ZÜRICHInventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
-
Patent number: 11401528Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.Type: GrantFiled: April 29, 2020Date of Patent: August 2, 2022Assignee: UNIVERSITÄT ZÜRICHInventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
-
Publication number: 20210071198Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP). matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerise II or RNA polymerase III.Type: ApplicationFiled: April 29, 2020Publication date: March 11, 2021Applicant: UNIVERSITÄT ZÜRICHInventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
-
Patent number: 10655145Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.Type: GrantFiled: March 21, 2018Date of Patent: May 19, 2020Assignee: UNIVERSITÄT ZÜRICHInventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
-
Publication number: 20190062784Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.Type: ApplicationFiled: March 21, 2018Publication date: February 28, 2019Applicant: UNIVERSITÄT ZÜRICHInventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
-
Patent number: 9944952Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.Type: GrantFiled: March 14, 2016Date of Patent: April 17, 2018Assignee: Universität ZürichInventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
-
Publication number: 20160194663Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.Type: ApplicationFiled: March 14, 2016Publication date: July 7, 2016Applicant: UNIVERSITÄT ZÜRICHInventors: Daniel D. PINSCHEWER, Lukas FLATZ, Andreas BERGTHALER, Rolf ZINKERNAGEL
-
Patent number: 9309289Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.Type: GrantFiled: October 23, 2013Date of Patent: April 12, 2016Assignee: Universitat ZurichInventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
-
Publication number: 20140050760Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.Type: ApplicationFiled: October 23, 2013Publication date: February 20, 2014Applicant: UNIVERSITAT ZURICHInventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
-
Patent number: 8592205Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.Type: GrantFiled: December 22, 2008Date of Patent: November 26, 2013Assignee: Universitat ZurichInventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
-
Publication number: 20100297172Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.Type: ApplicationFiled: December 22, 2008Publication date: November 25, 2010Inventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel